About Protein INSYN2B
Protein INSYN2B (INSYN2B) is a protein
from Homo sapiens identified by UniProt accession
A6NMK8, 535 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Protein INSYN2B |
| UniProt accession | A6NMK8 |
| Gene | INSYN2B |
| Organism | Homo sapiens |
| Length | 535 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (37)
Diseases linked to this target (Open Targets).
- bipolar disorder · score 0.38
- lymphocyte count · score 0.15
- adolescent idiopathic scoliosis · score 0.13
- DOCK2 deficiency · score 0.12
- verbal-numerical reasoning measurement · score 0.10
- metabolite measurement · score 0.09
- intelligence · score 0.09
- lung adenocarcinoma · score 0.07
- MODY · score 0.05
- diabetes mellitus, permanent neonatal 4 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NMK8-F1 | alphafold | PREDICTED | 52.58 | — |
Amino-acid sequence (535 residues)
MAQQNMKVRP VLLKRNSLES VEFVKQPHHR RSKSQQVRFK EDGTTKNPTG LAEVDVQTPE DPAVMGKTQA TRHHLPPTYS LSFPRSQKAG GFRNIAIQTS PSLRKHFPVF KRKRLTASKS LVEMPTASQS AIQVNGNLSE QDIVSSDLAY LRLAQHLEDG PRRVKVSHAF LPRVPKVQSN GPVSICLEAG TWRSLEKATA AIQVPDDIYH SPSWEARESA LSPDRSAEVS NSIHPLDDTR PGDGRRVTPL DSEKSTSCLN ATSVASHTPG TEELKPELLL PKDNSDDKDL GSLSSQSKET CVPSSPRTHS SPSQGSHSQP AHPGRASDCP SSSNNHQNLV SLKTNSASKS APGCQEQTAN NPTESDTLEF PNCPGSNHLP SSLSRSETKL QSNREISDIN QIHLARGELC DLQGRLQSVE ESLHSNQEKI KVLLNVIQDL EKARALTEGR NFYRTGQDLN NCSTCQNTAC IIYSVEYDFR QQEGRFHEVL QSLEEAEPVE EASPPPKSPA EPPAPEKQDL RRKTKKVKKK CFWWI
Explore Protein INSYN2B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets